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In the past 30 years or so, the introduction of 24-h
ambulatory blood pressure monitoring (ABPM) has enabled a
more comprehensive estimate of a patient’s true blood
pressure (BP) and its changes. Although this tool has been
used in the general population for the diagnosis of white
coat hypertension, its role in the clinical management of
patients with chronic and end-stage kidney disease is less
well defined. In patients with kidney disease, routine clinic
and dialysis center BP measurements may be poor indicators
of BP control. Loss of the normal nocturnal decline in BP is
also common. Moreover, there is increasing evidence that
this loss, which ABPM alone can detect, is associated with
poor renal and cardiovascular outcomes. To slow the
progression of renal disease and lessen cardiovascular
morbidity and mortality in patients with kidney disease, tight
BP control is needed. However, the traditional methods of
measuring BP intermittently in the medical setting may fail to
provide an accurate picture of BP load. Ambulatory or some
form of home BP monitoring should be more widely adopted
in patients with chronic and end-stage renal disease.
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Hypertension and chronic kidney disease (CKD) are inextri-
cably intertwined: the majority (70%) of individuals in the
general population who have an elevated serum creatinine are
hypertensive,1 and hypertension is both a cause and a
consequence of CKD. Most patients with CKD die of the
same cardiovascular diseases that afflict hypertensives with-
out CKD, and renal function is an independent predictor of
cardiovascular events.2,3 The importance of hypertension as a
determinant of the progression of CKD has been recognized
by official guidelines such as the Joint National Committee
7,4 the 2003 European Society of Hypertension–European
Society of Cardiology Hypertension Guidelines,5 and the
National Kidney Foundation Working Group Report on
Hypertension and Diabetes.6 Aggressive blood pressure (BP)
control is advised with some guidelines recommending that
BPs be targeted to less than 130/80 mmHg, or 10 mmHg
lower than in most other hypertensive populations.4–6 Yet,
despite this recognition that treating hypertension can
prevent many of its complications, BP remains poorly
controlled in many patients with renal insufficiency.7
In the past 30 years or so, the introduction of 24-h
ambulatory blood pressure monitoring (ABPM) has enabled
a more comprehensive estimate of a patient’s true BP and its
changes. A substantial number of prospective studies have
shown that ABPM predicts cardiovascular events better than
clinic-based readings, and also correlates more closely with
target organ damage. Whereas diurnal variation in BP,
characterized by a nocturnal ‘dip’ and morning surge, has
long been recognized, the advent of ABPM has also allowed
greater investigation into its prognostic significance. Loss
of the nocturnal decline in BP has been described in
hypertensives, diabetics, African Americans, and in patients
with sleep apnea and renal disease. In cross-sectional studies
and in a growing number of prospective trials, this loss,
which ABPM alone can detect, is associated with target organ
damage and adverse cardiovascular events.
ABPM has also been used to better define the relationship
between BP, target organ damage, and outcomes in patients
with chronic and end-stage renal disease (ESRD). Hyper-
tension in these patients shows some distinguishing features
on ABPM. First, the prevalence of non-dipping (elevated noctur-
nal BP) is very high. Second, in patients on dialysis, changes
in intravascular volume in the intra- and interdialytic
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period may result in marked swings of BP. Third, as in
patients without CKD, discrepancies between clinic and
home BP readings are common. The traditional methods of
measuring BP intermittently in the medical setting may
thus fail to provide an accurate picture of BP load, and
hence result in sub-optimal treatment. In this review, we will
examine the relationship between office and ambulatory BP
and their prognostic significance in patients with CKD and
ESRD. We will also review recent insights gained into
the prevalence, pathogenesis, and prognostic significance of
abnormalities in the diurnal variation of BP in this
population.
RELATIONSHIP BETWEEN OFFICE AND AMBULATORY
MEASUREMENTS IN PATIENTS WITH CKD
It is well established in studies of patients without CKD
that conventional clinic BP measurements may significantly
under- or overestimate the true BP.8–10 Although less well
described, discrepancies between clinic and ambulatory BPs
have also been reported in patients with CKD. Thus, in a
study of 232, mostly male patients with CKD, approximately
30% had clinic BPs that were higher than ABP measure-
ments, whereas 28% had clinic BPss that underestimated
ABP.11 White coat hypertension, defined by hypertension on
clinic measurements and normotension on ABPM, has been
reported in approximately 9% of diabetic patients with
microalbuminuria or macroalbuminuria.12 In pediatric
patients with treated hypertension and CKD, white coat
hypertension, defined by the 95th percentiles for clinic and
ABP readings, was found in 17% of patients. Masked
hypertension, where clinic BP underestimates the true BP,
was reported in another 5%.13
PROGNOSTIC SIGNIFICANCE OF OUT OF OFFICE
MEASUREMENTS
In numerous prospective studies, ABPM has proven to be
superior to clinic readings in predicting cardiovascular
outcomes. This superiority is due, in part, to ABPM’s ability
to identify subgroups of patients who are at higher and lower
risk of cardiovascular events than would be predicted by their
clinic measurements. ABPM is perhaps most widely used in
clinical practice for the diagnosis of white coat hypertension.
In comparison to normotensive patients, patients with white
coat hypertension do not appear to be at greater risk of
cardiovascular morbidity.8 Similar to patients with white
coat hypertension, treated hypertensives with elevated clinic
pressures but controlled ambulatory pressures have a lower
risk of adverse cardiovascular events than patients with
true refractory hypertension.14,15 In contrast, there is
evidence that masked hypertension is associated with worse
cardiovascular outcomes both in treated hypertensives and
patients found to be normotensive on clinic measurements.14
Similar studies examining the prognostic significance of
ABPM in patients with CKD are much needed. However,
there is evidence that home BP monitoring is superior
to clinic measurements in predicting outcomes in this
population. In a prospective cohort study of veterans with
CKD, home BP readings averaged over 1 week were superior
to standardized and routine clinic BP measurements in
predicting the composite end point of ESRD or death.
During a median follow-up of 3.5 years, 22% of patients with
masked hypertension (defined by routine measurements)
developed ESRD, whereas no patient with white coat
hypertension (defined by standardized or routine measure-
ments) progressed to ESRD. Even after adjustment for the
standardized clinic systolic BP and other risk factors, inclu-
ding proteinuria, age, and estimated GFR, home BP readings
were found to provide additional prognostic information on
the risk of progression to end-stage disease.16
ABPM AS A PREDICTOR OF TARGET ORGAN DAMAGE IN CKD
Additional support for ABPM’s role in the management
of CKD patients comes from small, cross-sectional studies
showing that ambulatory BPs correlate more closely than
clinic measurements with BP-related target organ damage. In
these studies, ABPM has either shown a stronger correlation
with left ventricular hypertrophy (LVH) than clinic-based
readings or has predicted LVH when no association could be
shown with clinic measurements. Twenty-four hours systolic
BP but not clinic readings predicted left ventricular mass
index (LVMI) in a study of 29 pediatric CKD patients.17 In
26 normotensive subjects with polycystic kidney disease
and relatively preserved renal function, 24-h systolic BP was
the only variable predictive of LVMI on multiple regression
analysis.18 Finally, ABPM showed a stronger correlation with
LVMI than single casual clinic measurements in a study of
85 CKD patients without a history of diabetes or vascular
disease.19 In addition, ABPs have been reported to correlate
more closely with proteinuria. In a study of 232 veterans with
CKD, Agarwal and Andersen20 found that ABPM had a
stronger correlation with proteinuria than home, standar-
dized, or single routine clinic readings taken by nurses
using an automated device. These studies, in which one or a
few clinic readings were compared with ABPM, suggest
that ABPM gives a better measure of BP control. However,
whether or not ABPM correlates better with target organ
damage depends to a large extent on how many clinic BP
readings are used in the comparison,21 and additional studies
are needed in patients with CKD to determine the predictive
advantage of ABPM in comparison to a larger number of
clinic readings.
RELATIONSHIP BETWEEN DIALYSIS CENTER MEASUREMENTS
AND ABPM
Hypertension’s contribution to cardiovascular morbidity and
mortality has been difficult to demonstrate in dialysis
patients.22 A paradoxical relationship between increased
mortality and lower BPs has been described and can be
attributed in part to an association between lower BP and
impaired cardiac function.23,24 However, dialysis center
measurements, used in many studies to explore the relation-
ship between hypertension and cardiovascular events, can be
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poor predictors of interdialytic BP control. This failure of
dialysis center measurements to accurately characterize BP
has likely also made it more difficult to define the prognostic
significance of hypertension in this population.
In hemodialysis patients, dialysis center measurements are
often poor indicators of interdialytic BP control. Of 71
dialysis patients in whom 44-h interdialytic BP monitoring
was compared with dialysis center measurements taken by
a nurse, 43% of patients classified as hypertensive by
predialysis systolic BP were normotensive on ABPM, while
25% of patients classified as normotensive by predialysis
systolic BP were hypertensive.25 Whereas predialysis BP
measurements tend to overestimate BP load, the relationship
between post-dialysis readings and BP control appears to be
more variable.26,27 In pediatric patients on hemodialysis
or peritoneal dialysis, casual BP measurements have also been
shown to be poor predictors of home BP levels.28,29
Because so many BP measurements are made during
dialysis, studies have attempted to determine if one reading
in particular or an average of readings can provide a more
accurate assessment of interdialytic BP. Mitra et al.30
compared measurements made on arrival, 10 min after
resting in a quiet room, at the onset of dialysis, end of
dialysis, and 20 min post-dialysis, with average 48-h ABP
readings in a group of 40 stable dialysis patients and found
that the 20 min post-dialysis BP reading was most represen-
tative of BP control in the interdialytic period. Conlon et al.31
averaged dialysis center readings from multiple visits and
showed that predialysis BPs averaged over 12 treatment
sessions showed a strong correlation with ABPM. Based on
the results of 48-h ABP recordings in 36 hemodialysis
patients, Coomer et al.27 developed a model to predict mean
BP based on age, sex, race, and pre- and postdialysis BP.
Finally, Agarwal and Lewis26 compared ABPM with a 2-week
average of dialysis center readings in 70 dialysis patients and
found that a 2-week average cutoff predialysis BP of 150/
80 mmHg or higher had 80% sensitivity and 67% specificity
to detect interdialytic hypertension as defined by an average
ABP of 135/85 mmHg or higher. Although these methods can
be used to obtain a better estimate of interdialytic control,
they cannot reliably determine BP in any individual patient.
Home BP monitoring and standardized predialysis BP
measurements, however, can aide in the assessment of BP
control. In a prospective cross-sectional study, home
BPs averaged over 1 week were shown to be superior to
routine dialysis center measurements averaged over 2 weeks
in predicting hypertension on 44-h ABPM (defined as an
awake BP greater than or equal to 135/85 mmHg). Standar-
dized predialysis BP averaged over 2 weeks, although time
intensive for the dialysis staff, had similar predictive ability as
home measurements.32
REASONS FOR POOR CORRELATION BETWEEN DIALYSIS AND
AMBULATORY BPs
The poor correlation between dialysis and ABPM readings
is explained in part by changes in BP that occur in the
interdialytic period, which cannot be captured by measure-
ments made in the dialysis center. Santos et al.25 studied BP
in the interdialytic period in 71 stable hemodialysis patients
and found a statistically significant increase in average
daytime and night time BPs from the first to second day of
the interdialytic period. In a study of 20 mostly black
hemodialysis patients, Agarwal33 reported a similar pattern of
BP changes and also observed a decrease in BP in the period
after dialysis, a finding that has been described by
others.27,33,34 In addition to these likely volume-induced
changes in BP, improper measurement technique and a
white coat effect may also contribute to the poor correlation
between dialysis center and ABP readings. In a cross-sectional
study of 270 hemodialysis patients, routine dialysis center
measurements were 14.3/7 mmHg higher than those taken by
a nurse following standard American Heart Association
guidelines for BP measurement, and in 53% of patients,
routine measurements were more than 10 mmHg greater
than standardized readings (Figure 1).35 A marked difference
in BP (420/10 mmHg) between ABP readings taken in the
6 h predialysis and BP measured immediately after arrival was
also found in 41% of patients in a study by Mitra et al.30 This
difference persisted in seven of 15 patients after repeat BP
measurement after 10 min in a quiet room, illustrating both
the importance of appropriate BP measurement technique
and suggesting a possible white coat effect. Finally, the
practice of withholding BP medications on the day of dialysis
may also contribute to the poor correlation between dialysis-
based readings and ABPM. Studies specifically addressing this
issue, however, are currently lacking.
PROGNOSTIC SIGNIFICANCE OF ABPM IN ESRD
As in patients with CKD, there is evidence from cross-
sectional studies that ABPM is superior to dialysis center
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Figure 1 | Systolic BP difference between standardized and
‘usual’ dialysis center BP measurements in 270 hemodialysis
patients. (Adapted from Rahman et al. Am J Kidney Dis 2002; 39:
1226–1230.)
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measurements in predicting target organ damage in patients
with ESRD. In a small study of patients on peritoneal and
hemodialysis, ABP but not office BP was associated with
LVM.36 LVMI and LV wall thickness were more strongly
correlated with ABP than the average of two casual dialysis
center measurements in a study of non-diabetic hemodialysis
patients.37 In perhaps the largest study to date, Agarwal
et al.38 reported that 44-h ABPM and home BP monitoring,
although weak determinants of LVH, were superior to a
2-week average of standardized and routine dialysis center
measurements in 140 chronic hemodialysis patients. How-
ever, the predictive advantage of ABPM for LVH was lost in
two studies in which comparisons were made with a greater
number of dialysis center readings. The correlation between
LVH and BP was similar using ABPM and an average of 12
standardized predialysis measurements in a study of 35 stable
hemodialysis patients.31 In a second study of 64 non-diabetic
hemodialysis patients without heart failure, including the
results of 24-h ABPM to a model already containing the
average of 12 routine predialysis measurements did not add
significantly to the correlation with LVMI.39
In addition to these studies, three prognostic studies have
also used ABPM to explore the relationship between BP and
cardiovascular morbidity and mortality in hemodialysis
patients. The three studies were small, and although all
showed an association between ABPM and outcome, none
reported a relationship between outcome and predialysis
measurements.40–42 The exact components of ABP that
have been predictive of outcome have varied, although one
observation has emerged consistently: loss of the normal
nocturnal decline in BP carries a poor prognosis. These
studies highlight the prognostic significance of disruptions in
diurnal variation in patients with CKD and ESRD, the topic
of the remainder of this review.
DIURNAL VARIATION IN BP AND ITS DISRUPTION IN KIDNEY
DISEASE
In the general population, BP falls on average by 10–20%
during sleep, a phenomenon referred to as ‘dipping’. In about
25% of healthy subjects, and in certain disease states,
however, a loss of diurnal variation in BP (Figure 2) has
been reported (non-dipping). Non-dipping is particularly
common in both children and adults with CKD, and an
inverse relationship between GFR and the prevalence of non-
dipping has been described (Figure 3).17,43 Although the
reported prevalence of non-dipping in adults with CKD
varies, rates of 50% or higher have been observed at the
earliest stages of disease, whereas rates of more than 80%
have been observed in patients on dialysis.43
PATHOGENESIS OF THE DIMINISHED NOCTURNAL FALL
IN CKD AND ESRD
Whether or not the diseased kidney itself directly causes
abnormalities in diurnal variation is unknown and studies
attempting to answer this question have, to date, produced
somewhat mixed results. Portaluppi et al.44 performed ABPM
following the discontinuation of BP medications in 30 non-
diabetic CKD patients and 30 controls matched by sex, age,
and mean 24-h BP. Although controls exhibited an average
nocturnal decline in systolic and diastolic BP, nocturnal
systolic and diastolic BP increased in patients with CKD,
suggesting a role for the kidney in the pathogenesis of this
disorder. In a study by Baumgart et al.,45 61 patients with
CKD, ESRD on dialysis, or post-renal transplant were
matched by age, sex, systolic office BP, and use of
antihypertensive medication to 61 controls with normal
renal function. Compared with controls, the nocturnal
decline in BP was diminished in all patient groups with
renal disease. Taking a somewhat different approach, van de
Borne et al.46 attempted to isolate the role of the diseased
kidney by performing ABPM in a small group of dialysis
patients carefully selected to exclude many of the causes and
complications of kidney disease known or hypothesized to
affect diurnal variation. In this trial, dialysis patients with
diabetes, hypertension, an inability to ambulate, heart failure,
cardiac arrhythmias, psychiatric diseases, irregular sleep–wake
schedule, transmeridian travel, past or present use of
erythropoietin, and use of any medication other than calcium
and vitamin D were excluded and hemodialysis patients
were matched with controls by age, sex, and casual systolic
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Figure 2 | A non-dipping pattern of BP is seen on ABPM in a CKD
patient with masked hypertension.
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Figure 3 | Prevalence of non-dipping in essential hypertension
and at various stages of renal dysfunction. (Adapted from Farmer
et al. Nephrol Dial Transplant 1997; 12: 2301–2307.)
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BP measurement. In contrast with the findings of others,
van de Borne et al. showed that in this select group of ESRD
patients, the nocturnal decline in BP was in fact preserved.
In non-CKD patients, an association between non-
dipping and volume expansion has been described. In salt-
sensitive subjects, who tend to be non-dippers, the nocturnal
fall in BP is significantly increased by a low sodium diet.47
Diuretics can also restore dipping status, as evidenced by an
increase in the nocturnal fall in systolic and diastolic BP
following thiazide diuretic administration in patients with
essential hypertension.48 In ESRD patients, a statistically
significant increase in the night/day ratio49 and a statistically
significant decrease in the awake–sleep difference in BP30 has
been reported from the first to the second day after dialysis.
In a study of 71 unselected hemodialysis patients, a trend
toward an increased prevalence of non-dipping was also seen
that did not reach statistical significance.25 However, switch-
ing patients from thrice weekly to daily dialysis, although
effective in reducing BP and extracellular body water, was not
found to affect dipping status.50 A high prevalence of non-
dipping has also been reported in patients receiving long,
slow home hemodialysis thrice weekly.51 Hence, factors other
than volume likely also play a role.
Abnormal sympathetic nervous system (SNS) activity has
been reported to contribute to the non-dipping pattern of BP
in non-CKD patients. In healthy subjects, SNS activity falls
during sleep, as evidenced by a decrease in urinary and
plasma catecholamine levels and in muscle sympathetic nerve
activity (non-REM sleep).52–55 In non-dippers without CKD,
this nocturnal fall in urinary epinephrine and norepinephrine
levels is diminished.56 As increased SNS activity has been
described in patients with kidney disease,57 it is possible that
loss of diurnal variation in this population is due, in part,
to abnormal SNS activity as well.
In addition to these factors, many others, known to cause
and or arise as a complication of kidney disease, may also
play a role in this diminished nocturnal decline in BP seen in
patients with renal disease. Diabetes and autonomic dysfunc-
tion, operating through increased volume, nocturnal SNS
activity, or via other mechanisms, are associated with non-
dipping and are prevalent in the CKD and ESRD popula-
tions. Low levels of physical activity during the daytime58 and
poor sleep quality59 have been linked to a diminished night
time fall in BP. Furthermore, sleep apnea, which has been
reported in 15% of an unselected group of dialysis patients
and at higher rates in dialysis patients complaining of sleep
problems, is associated with nocturnal hypertension.60,61 A
smaller decline in nocturnal BP has also been described in
treated versus untreated hypertensives, possibly owing to the
waning effect of antihypertensive medications taken in the
morning.62
PROGNOSTIC SIGNIFICANCE OF THE NON-DIPPING PATTERN
IN CKD AND ESRD
A loss of diurnal variation in BP has been associated with a
poor renal prognosis. In cross-sectional studies of patients
with established kidney disease, a diminished sleep-to-wake
ratio of BP has been associated with greater proteinuria and
diminished renal function.20,43,63 These observations have
been confirmed in some longitudinal trials. In normotensive
type I diabetics, the absence of a normal nocturnal fall in
systolic blood predicted the later development of micro-
albuminuria.64 In a 3-year longitudinal study of 28
non-dippers and 20 dippers with hypertension and CKD,
non-dipping at baseline was predictive of a faster decline in
renal function and a greater increase in proteinuria.65 In a
second study of 95 patients with non-diabetic kidney disease,
non-dipping at baseline was also associated with a faster rate
of progression of renal disease during 3 years of follow-up.66
However, in this study non-dipping was associated with
a higher creatinine and greater proteinuria at baseline as well,
making it hard to determine what role, if any, non-dipping
played in the progression of renal disease.
Loss of the nocturnal decline in BP has also been linked to
LVH, adverse cardiovascular outcomes, and all-cause mor-
tality in patients with ESRD. In a study of 59 hemodialysis
patients, a correlation was found between the day/night
ratio and LVMI,67 whereas in peritoneal dialysis patients an
elevated night time BP load was the sole predictor of LVH.68
As described, three prospective studies have reported an
association between loss of the nocturnal decline in BP and
adverse outcomes. In a cohort of 80 dialysis patients without
a history of congestive heart failure or significant cardio-
vascular disease, non-dipping status was associated with an
increased adjusted hazard ratio for cardiovascular morbidity
and mortality.41 A second study of 57 hypertensive ESRD
patients without a history of systolic cardiac dysfunction or
valvular disease found that after controlling for age, sex, and
cardiovascular history, an elevated nocturnal blood systolic
BP was associated with increased cardiovascular mortality.40
Finally, in a study by Tripepi et al.,42 168 dialysis patients
without a history of diabetes, cardiovascular disease, or
clinical evidence of heart failure were followed for 38 months.
In a multi-regression analysis model not including LVH,
an association between the highest night/day BP tertile and
increased cardiovascular and all-cause mortality was found.
In contrast, the predialysis BP averaged over 1 month did not
predict events.
WHY SHOULD NON-DIPPING INCREASE RISK?
Why this loss of nocturnal variation carries such a poor
prognosis is unknown. In the study by Tripepi et al.,42 24-h
systolic BP was also greater in subjects with higher night/day
systolic ratios. Hence, some of the increased risk associated
with elevated nocturnal pressures may simply be due to the
greater 24-h BP load associated with this elevation. It is also
possible that the absence of a nocturnal decline in BP is not
itself a cause of adverse outcomes, but is instead just a marker
of sicker patients. As described above, less daytime activity,
poorer sleep quality, sleep apnea, autonomic dysfunction,
volume overload, and the use of antihypertensive medica-
tions have all been associated with loss of diurnal variation in
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BP. Finally, although dipping status may be an important
predictor of outcome, it is interesting to note that dipping
status itself is not very reproducible. In 21 hemodialysis
patients in whom dry weight and BP medications were held
constant, up to 43% changed their dipping status from the
first to second interdialytic day, whereas up to 38% changed
dipping status on repeat testing at least 4 weeks later.69 In
patients with polycystic kidney disease and mild renal
impairment, only approximately 40% of patients maintained
their initial dipping status on repeat testing, although
dipping status in this study was divided into quartiles and
BP medications changes that occurred during the course
of the study may have confounded these results.70 Such
findings, coupled with the observation that the correlation
between end-organ damage and non-dipping is strongest in
patients with a reproducible non-dipping pattern,71 suggest-
ing that in trials and in clinical practice, dipping status
should probably be defined by or confirmed with repeat
testing.
RESTORING THE NOCTURNAL DIP IN BP
Just as BP can be lowered in patients with CKD, there is some
evidence that dipping status can be restored. Changing the
timing of administration of the calcium channel blocker,
isradipine, from morning to night, improved the nocturnal
decline in BP in patients with kidney disease.72 An increased
nocturnal decline in systolic BP was seen at 6-month follow-
up in hypertensive children with kidney disease started on
an angiotensin converting enzyme inhibition.63 As noted
above, diuretics and a low sodium diet selectively lower
nocturnal BPs in non-CKD patients with salt-sensitive
hypertension, an effect that may also occur in patients with
CKD. There is also evidence that kidney transplantation
restores the nocturnal decline in BP. In a cross-sectional
study of 45 renal transplant patients, Gatzka et al.73 found
that with increasing time from transplant, the number of
patients displaying a normal nocturnal decline in BP
increased. The use of cyclosporine post-transplant, however,
has been associated with worsening nocturnal pressures. In
a cross-sectional study of 46 renal transplant patients
randomly assigned to cyclosporine or azithioprine 1 year
post-transplant, nocturnal pressures were significantly higher
in cyclosporine-treated patients.74 An improvement in
overall BP control and nocturnal BPs was also reported in
18 renal transplant patients randomized to conversion from
a cyclosporine to azathioprine-based immunosuppressive
regimen.75
CONCLUSION
In the past 30 years or so, the introduction of ABPM has
enabled a more comprehensive estimate of a patient’s true BP
and its changes. Although ABPM is a useful tool for studying
the relationship between BP and outcomes in patients with
kidney disease, it has been underutilized. The relationship
between BP and mortality in patients on hemodialysis
remains a major unresolved question. Studies using conven-
tional BP measurements have produced conflicting results
and future studies examining this relationship or assessing
the impact of treating hypertension in patients on hemo-
dialysis should use either ambulatory or home BP monitor-
ing. The prognostic significance of ambulatory and home BP
readings in patients with CKD has not been adequately
studied, and their role in directing antihypertensive therapies
also needs to be addressed. Finally, studies are needed to
determine if restoration of the nocturnal decline in BP will
translate into improved renal and cardiovascular outcomes
above and beyond those obtained from reducing the overall
BP load. In the meantime, ambulatory or some form of home
BP monitoring should be used to obtain a more accurate
picture of BP control in patients with chronic and ESRD.
Clinic BPs frequently under- or overestimate the true BP in
CKD patients and dialysis center BP measurements, although
widely used to guide therapy, are poor indicators of
interdialytic BPs. Tight BP control is needed to limit the
progression of renal disease and lessen cardiovascular
morbidity and mortality in patients with kidney disease.
However, to achieve this goal, BP must be accurately
measured. Ambulatory or some form of home BP monitor-
ing should be more widely adopted in patients with chronic
and ESRD.
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